Wednesday 08 May 2024
Internal Reference Number: FOI_6335
Date Request Received: 21/10/2021 00:00:00
Date Request Replied To: 17/11/2021 00:00:00
This response was sent via: By Email
Request Summary: Breast Cancer Treatment
Request Category: Companies
| Question Number 1: How many patients have been treated for breast cancer (any stage) in the past 3 months with the systemic anti-cancer therapies listed below? • Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) as a single agent • Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) • Abemaciclib + Fulvestrant • Anthracycline (e.g. doxorubicin or epirubicin) as a single agent • Atezolizumab +Nab-paclitaxel/Paclitaxel • Capecitabine as a single agent • Carboplatin or Cisplatin as a single agent • Eribulin as a single agent or in combination • Everolimus + Exemestane • Fluorouracil • Fulvestrant as a single agent • Goserelin • Lapatinib • Neratinib • Olaparib • Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) • Palbociclib + Fulvestrant • Pertuzumab + Trastuzumab + Docetaxel • Platinum (e.g. carboplatin or cisplatin) as a single agent • Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) • Ribociclib + Fulvestrant • Talazoparib • Tamoxifen • Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent • Transtuzumab as a single agent • Trastuzumab emtansine • Transtuzumab deruxtecan • Any other active systemic anti-cancer therapy | |
| Answer To Question 1: Aromatase inhibitor- unable to respond as could be provided via multiple routes Abemaciclib +AI- 1 Abemaciclb+ fulvestrant- 2 Anthracycline single agent- 0 Atezolizumab + Nab-paclitaxel- 4 Capecitabine single agent- 21 Carboplatin/cisplatin and Platinum single agent- 0 Eribulin- 0 Everolimus + exemestane- 0 Fluorouracil-0 Fulvestrant single agent-4 Goserilin- unable to answer as multiple routes of supply and stock on some areas Lapatinib-0 Netatinib-1 Olaparib- 0 Palbociclib+AI- 33 Palbociclib +fulvestrant- 3 Pertuzumab+Trastuzumab+docetaxel- 6 Ribociclib (both options)- 0 Talazoparib-0 Tamoxifen- unable to respond as could be provided via multiple routes Taxane- 12 Trastuzumab single agent- 9 Trastuzumab emtansine-5 Trastuzumab deruxtecan-0 Any other- 195 patient episodes, number of individual patients not recorded. | |
| Question Number 2: In the past 3 months, how many early/locally advanced (Stages I to IIIc) breast cancer patients were treated with an Aromatase Inhibitor (anastrozole, exemestane, Letrozole) as a single agent? | |
| Answer To Question 2: Unable to answer as the reports do not list the staging | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
